Aarti Pharmalabs Ltd logo

Aarti Pharmalabs Ltd

AARTIPHARM NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹7,966 Cr
Volatility
High Risk
P/E Ratio
37.2
EBITDA
₹366 Cr
Return on Equity
13.69%
Debt to Equity
0.35
Book Value
₹234.3
EPS
₹24.86
52W High
₹946.1
52W Low
₹585

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Aarti Pharmalabs Ltd insights

46 extracted metrics + investor summaries across FY12–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Weaknesses

3
  • Stock is trading at 3.73 times its book value
  • Company has a low return on equity of 11.9% over last 3 years.
  • Promoter holding has decreased over last 3 years: -3.12%

Growth Rate

Revenue Growth
-14.39% ↘
Net Income Growth
-29.97% ↘
Cash Flow Change
53.25% ↗
ROE
10.94% ↘
ROCE
2.38% ↘
EBITDA Margin (Avg.)
-10.70% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 43d ago
AI opinion · based on fundamentals
Risk high

Aarti Pharmalabs Ltd is a healthcare company with a market cap of ₹6,378 Cr trading at a PE of 36.7x. The company is experiencing a significant earnings contraction with TTM profit declining 35% and sales declining 14%, while its 3-year stock CAGR of 25% reflects prior momentum that has reversed sharply with a -22% return over the last year.

Bull Case 7
  • 3-year stock CAGR of 25% indicates strong medium-term wealth creation for earlier investors despite recent correction
  • 5-year average ROE of 13% suggests the business has historically generated reasonable returns on shareholder equity
  • 3-year average ROE of 12% remains above cost of equity for most Indian companies, indicating underlying business quality
  • Market cap of ₹6,378 Cr provides reasonable scale and liquidity for institutional participation
  • Dividend yield of 0.21% shows the company maintains a dividend payout policy despite earnings pressure
  • The -22% stock decline in the last 1 year may offer a more attractive entry valuation compared to prior highs for contrarian investors
  • Operating in the healthcare/pharma sector which benefits from structural domestic and export demand tailwinds in India
Bear Case 8
  • TTM compounded profit growth of -35% indicates severe earnings deterioration in the most recent period
  • TTM compounded sales growth of -14% shows meaningful revenue contraction, not just margin compression
  • PE ratio of 36.7x is elevated given that earnings are declining, implying the stock is priced for growth that is not materializing
  • Last year ROE dropped to 9% from a 3-year average of 12%, showing declining capital efficiency
  • Price-to-book of 3.01x is high relative to the low ROE of 11.9% over 3 years, suggesting stretched valuation on asset basis
  • 3-year compounded profit growth of -3% indicates earnings stagnation even over a medium-term horizon
  • 3-year compounded sales growth of -2% shows the topline has been essentially flat over three years
  • Stock has declined 22% over the past year, reflecting sustained negative market sentiment and potential de-rating

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 43d ago
Positives 1
  • New Tarapur manufacturing block Jun 30

    Aarti Pharmalabs inaugurated a new manufacturing block at Tarapur Unit 5, adding 3600 TPA capacity for Xanthine derivatives, bringing total capacity to 9600 TPA.

TL;DR: Aarti Pharmalabs is executing on capacity expansion with a meaningful 60% increase in Xanthine derivatives capacity at Tarapur. No visible headwinds in recent news flow. The trend is constructive as the company invests in growth, though limited news coverage makes it difficult to assess broader operational performance.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
458
440
449
506
555
458
538
564
386
418
432
583
536
Expenses
373
352
353
388
459
364
409
418
293
344
330
470
400
Operating Profit
85
88
96
118
96
94
129
146
93
74
102
113
136
OPM %
19%
20%
21%
23%
17%
20%
24%
26%
24%
18%
24%
19%
25%
Other Income
0
1
1
2
2
4
5
-2
2
0
2
14
8
Interest
4
4
4
5
5
6
10
7
7
11
13
17
13
Depreciation
17
18
19
19
20
21
23
23
23
25
29
28
30
PBT
64
67
74
96
74
72
101
115
65
39
63
82
101
Tax %
26%
23%
29%
32%
25%
24%
26%
23%
24%
28%
24%
25%
25%
Net Profit
47
52
53
65
55
55
74
88
50
28
48
61
76
EPS in Rs
5.2
5.72
5.82
7.2
6.12
6.03
8.16
9.75
5.46
3.08
5.29
6.74
8.4
Figures in ₹ Crores

Profit & Loss

  Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
0
1,200
1,945
1,853
2,115
1,819
1,969
Expenses
0
993
1,603
1,467
1,651
1,450
1,543
Operating Profit
0
207
342
386
464
369
426
OPM %
—
17%
18%
21%
22%
20%
22%
Other Income
0
3
2
5
10
15
23
Interest
0
12
21
17
27
47
53
Depreciation
0
42
63
73
87
104
112
PBT
0
155
261
300
361
233
284
Tax %
—
21%
26%
28%
24%
25%
—
Net Profit
0
122
193
217
272
175
213
EPS in Rs
—
—
21.35
23.93
30.05
19.27
23.51
Div. Payout %
—
0%
9%
13%
17%
18%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0.25
0.25
45
45
45
45
Reserves
0
1,386
1,513
1,712
1,945
2,079
Borrowings
0
338
215
285
413
754
Other Liabilities
0
315
470
540
503
603
Total Liabilities
0
2,040
2,244
2,582
2,906
3,482
Fixed Assets
0
782
926
1,033
1,137
1,525
CWIP
0
187
102
137
374
305
Investments
0
32
87
107
77
194
Other Assets
0
1,038
1,130
1,305
1,319
1,457
Total Assets
0
2,040
2,244
2,582
2,906
3,482
Figures in ₹ Crores

Cash Flow

  Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
-44
250
216
332
262
Investing
0
-139
-158
-215
-414
-431
Financing
0
260
-163
10
65
171
Net Cash Flow
0
78
-71
12
-17
2
Free Cash Flow
0
-185
130
18
-112
-186
CFO/OP
—
-11
91
71
85
84
Figures in ₹ Crores

Ratios

  Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
—
115
84
102
99
117
Inventory Days
—
272
188
230
190
280
Days Payable
—
123
106
135
90
146
Cash Conversion Cycle
—
264
166
197
200
251
Working Capital Days
—
111
94
110
105
90
ROCE %
—
19%
16%
17%
17%
11%

Shareholding Pattern

As of Jun 2026
Promoters 42.86%
Public 34.39%
FIIs 8.17%
Others 7.35%
DIIs 7.22%
Government 0.01%
Total 100.00%
  Jan 2023Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
44.16%
45.98%
45.98%
46.30%
46.46%
46.46%
46.46%
46.10%
44.66%
44.29%
43.72%
42.88%
43.10%
43.08%
42.86%
FIIs
0.00%
0.00%
0.00%
0.00%
8.16%
8.32%
7.06%
7.38%
8.64%
7.36%
7.35%
8.02%
7.68%
8.39%
8.17%
DIIs
14.73%
13.70%
10.66%
10.51%
9.91%
9.97%
11.47%
11.35%
10.36%
7.53%
7.80%
6.96%
7.66%
7.41%
7.22%
Government
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
Public
24.66%
28.35%
30.23%
29.13%
29.74%
29.71%
29.57%
29.45%
30.39%
34.10%
34.43%
35.39%
34.85%
34.29%
34.39%
Others
16.44%
11.96%
13.12%
14.04%
5.72%
5.52%
5.43%
5.71%
5.94%
6.71%
6.69%
6.74%
6.70%
6.82%
7.35%
No. of Shareholders
3,05,456
2,76,664
2,58,236
2,26,286
2,15,796
2,04,122
1,89,012
1,85,436
1,85,111
1,96,314
1,87,039
1,90,655
1,84,489
1,79,373
1,76,506

Documents

Frequently Asked Questions about Aarti Pharmalabs Ltd

What does Aarti Pharmalabs Ltd do?
Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals[1]
Where is Aarti Pharmalabs Ltd (AARTIPHARM) listed?
Aarti Pharmalabs Ltd is listed on the Indian stock exchanges. It is listed on NSE: AARTIPHARM and BSE: 543748. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Aarti Pharmalabs Ltd belong to?
Aarti Pharmalabs Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Aarti Pharmalabs Ltd?
Aarti Pharmalabs Ltd has a market capitalisation of approximately ₹7966.10 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Aarti Pharmalabs Ltd?
The Price-to-Earnings (PE) ratio of Aarti Pharmalabs Ltd is 37.20. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Aarti Pharmalabs Ltd?
Over the past 52 weeks, Aarti Pharmalabs Ltd has traded between a low of ₹585 and a high of ₹946.1. This range helps investors understand the stock's price volatility and recent trading levels.
Does Aarti Pharmalabs Ltd pay dividends?
Yes, Aarti Pharmalabs Ltd has a dividend yield of 0.17%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Aarti Pharmalabs Ltd?
Aarti Pharmalabs Ltd has a Return on Equity (ROE) of 13.69%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Aarti Pharmalabs Ltd on Tapetide?
On Tapetide, you can view Aarti Pharmalabs Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals[1]

Website aartipharmalabs.com
CEO Ms. Hetal Gogri Gala
Employees 2,162
Listed 2023-01-30
Face Value ₹ 5
Issued Size 9,06,41,224

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List